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Digoxin is a drug with a narrow therapeutic range. We present an 88-year-old woman with chronic
kidney failure who was suspected of having digoxin intoxication when she developed nausea, vomiting,
loss of appetite, lethargy, and unconsciousness after taking digoxin 0.25 mg daily for 1 week. A blood test
revealed a high digoxin concentration of 5.42 ng/mL. The patient experienced bradycardia, hypotension,
acute renal failure, and hyperkalemia. Electroencephalography revealed global brain dysfunction. She
was given a temporary pacemaker and several rounds of dialysis. The digoxin concentration in the
patient’s blood was monitored every 2 days, and she gradually regained consciousness as the level of
digoxin decreased to the normal range within 2 weeks. Patients with chronic renal failure should be
monitored and tested before the administration of digoxin to titrate the dose. The drug plasma
concentration should be carefully monitored for 5e7 days after drug administration. Patients’ renal
function, associated electrolyte concentrations, and drug levels should be tested regularly to ensure drug
safety.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Digoxin is a drug with a narrow therapeutic range. Nevertheless,
with the progress in pharmacokinetics, the serum concentration of
digoxin can be maintained at a safe level to reduce the possibility of
digoxin toxicity.
The symptoms of digoxin toxicity include blurred vision, diar-
rhea, and nausea in mild cases, and unconsciousness and vertigo in
severe cases. Therefore, it is extremely important that extra
attention be paid to elderly patients who regularly receive digoxin.
These patients should receive special instructions on dosage and
administration time. Although cases of digoxin toxicity are
common, few studies have described one of the adverse effects of
digoxin toxicitydencephalopathy. The present article focuses on
a patient with chronic kidney disease, who underwent digoxin
treatment for 1 week and subsequently developed severe digoxin
toxicity with encephalopathy and bradycardia, which persisted for
2 weeks. We also discuss the safety concerns related to the use of
digoxin in such patients.y, Buddhist Dalin Tzu Chi
iayi, Taiwan. Tel.: þ886 5
uang).
ddhist Compassion Relief Tzu Chi2. Case report
An 88-year-old womanwith a medical history of chronic kidney
disease (blood urea nitrogen, 55 mg/dL; creatinine, 2.5 mg/dL) and
heart failure was referred to the emergency room of our hospital
because of unconsciousness (Glasgow Coma Scale score: E2, V4,
M5e6) and oliguria. In the emergency room, she was diagnosed
with sinus bradycardia (heart rate, 56 beats/min); hypotension
(blood pressure, 90/47 mmHg); and acute renal failure (blood urea
nitrogen, 148 mg/dL; creatinine, 6.6 mg/dL). She was transferred to
the respiratory intensive care unit for observation and treatment.
Her recent medication history revealed that she had been taking
digoxin 0.25 mg daily for heart failure for 1 week and had subse-
quently developed nausea, vomiting, loss of appetite, and lethargy;
hence, digoxin toxicity was suspected. A blood test revealed that
the serum digoxin concentration was 5.42 ng/mL (Table 1).
The patient experienced bradycardia, hypotension, acute renal
failure, and hyperkalemia (potassium level, 6.64 mmol/L) in the
respiratory intensive care unit. As hyperkalemia had the potential
to worsen the bradycardia, emergency dialysis was performed to
lower the potassium levels, and a temporary cardiac pacemaker
was implanted to manage the bradycardia and hypotension. After
several rounds of dialysis, renal function was restored to her
baseline level, and her urine volume increased. Subsequently, theFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Biochemical data obtained during the patient’s admission.
Test/value Normal
range
Baseline
value
At the time
of admission
Day 2 Day 3 Day 6 Day 9 Day 12 Day 19
BUN (mg/dL) 6e20 55 148 d 95 80 110 45
CRE (mg/dL) 0.5e1.2 2.5 6.6 d 5.2 4 4.2 2.1
K (mEq/L) 3.4e5.1 5.09 5.8 6.64 3.44 4.09 3.38 2.91 4.00
Mg (mg/dL) 1.3e2.5 d d 6.9 4.3 3.6 3.8
Digoxin (ng/mL) 0.8e2.0 d 5.42 4.45 3.17 2.32 1.53 1.22
GCS (total score) 4 11 10 11 13 13
BUN¼ blood urea nitrogen; CRE¼ creatinine; GCS¼Glasgow Coma Scale; K¼ potassium; Mg¼magnesium.
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scious, computed tomography of the head was performed to rule
out the possibility of stroke. Electroencephalography revealed
global brain dysfunction. Her blood digoxin concentration was
monitored every 2 days, and the patient gradually regained
consciousness as the blood level of digoxin decreased to the normal
range within 2 weeks (Table 1). During this period, the patient’s
heart rate also returned to normal. She was discharged from the
hospital a week after the removal of the temporary pacemaker.
3. Discussion
The diagnosis of digoxin-induced encephalopathy in our
patient was conﬁrmed by exclusion of other organic brain lesions
and recovery of consciousness after the decline in digoxin levels.
The mechanism of the pharmacological action [1] of digoxin is the
inhibition of the a-subunit of Naþ/Kþ ATPase that enhances
myocardial contractility. Moreover, digoxin increases vagal
activity, leading to a decrease in the heart rate [2] by means of
a decrease of intraventricular conduction and increase of the
refractory period and diastolic ﬁlling time. Both digoxin and
digitoxin, the unaltered form of digoxin, are reabsorbed by the
small intestine. However, because digoxin has a long half-life
compared with its dosage interval and a very long distribution
phase, simple pharmacokinetic equations can be used to individ-
ualize dosages when postdistribution serum concentrations are
used. Digoxin is excreted about 50e70% unchanged by the
kidneys, and the elimination half-life is about 1.5e2 days in adult
anuric patients, and 3.5e5 days in patients with renal impairment
[3e5]. As digoxin has a narrow therapeutic index, its therapeutic
and toxic effects should be monitored with the serum digoxin
concentration (SDC). The standard SDC for treatment of atrial
ﬁbrillation with a rapid ventricular rate is 1.0e2.0 ng/mL, and forTable 2
Summary of the digoxin-induced encephalopathy [8].
Case
number
Age (y) Gender Symptom Digoxin
level (ug/L)
Stop digoxin le
1 68 Female 1-wk history of profound
somnolence
>5 1 wk later, digo
back to 0.3 ug/
2 66 Female Unconsciousness 4.2 3 d later, digox
0.7 ug/L
Our case 88 Female Unconsciousness
and oliguria
5.42 2 wk later, digo
back to 1.22 ugsymptoms of congestive heart failure, it is <1.0 ng/mL. However,
some studies have suggested that a high SDC (>1.0 ng/mL) leads to
increased mortality [6].
In one study [7], 6e23% of admitted patients had digoxin
intoxication, and the mortality rate was up to 41%. Digoxin intoxi-
cation presents with the following symptoms [8]dpsychological
symptoms: delirium, fatigue, exhaustion, confusion, dizziness, and
encephalopathy; visual symptoms: blurred or yellow vision;
gastrointestinal symptoms: nausea, vomiting, abdominal pain, and
loss of appetite; and cardiac symptoms: abnormally high electrical
conductivity and autorhythmicity of the cardiac myocytes. When
a patient shows any symptoms of digoxin intoxication, the blood
digoxin concentration should be checked immediately.
In our patient, acute renal failure led to the decrease in the
amount of body ﬂuid, which intensiﬁed the digoxin intoxication
and then caused the gastrointestinal side effect. The complications
included bradycardia, hypotension, and encephalopathy. The
symptoms of intoxication included vomiting, ventricular tachy-
cardia, ventricular ﬁbrillation, sinoatrial node arrest, atrioventric-
ular block, visual impairment, weakness, sinus bradycardia, atrial
ﬁbrillation, and ventricular arrhythmia.
Digoxin-induced encephalopathy was also reported in two
clinical cases published by Greenway et al [8] in 1995. We
summarize and compare these three cases in Table 2.
Previous studies [9e11] have indicated that the most commonly
observed symptoms of digoxin intoxication include lethargy and
loss of consciousness. Elderly patients are generally at a much
higher risk of digoxin intoxication than younger individuals.
Moreover, in patients with chronic kidney disease, imbalances of
body ﬂuids and electrolytes often occur, which makes evaluation of
the digoxin dosage extremely critical. During dose titration,
extreme care should be taken with regard to renal function and
electrolyte levels.vel Serum creatinine level Medication record
xin level was
L
Not mentioned in the article Furosemide 120 mg,
spironolactone 100 mg,
prednisolone 5 mg, ranitidine
150 mg, digoxin 250 ug, all
daily, with isosorbide
mononitrate 20 mg and
nifedipine SR 10 mg both twice
daily
in level was Not mentioned in the article Digoxin 250 ug daily, captopril
25 mg tid, furosemide 250 mg
bid, warfarin 4 mg daily
xin level was
/L
5.2 mg/dL Digoxin 250 ug daily,
furosemide 40 mg daily,
clopidogrel 75 mg, perindopril
& indapamide 2 mg &
0.625 mg/tab daily, isosorbide
mononitrate 20 mg twice daily
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medication before intoxication; thus, the possibility of a drug
interaction was automatically eliminated. The patient’s poor renal
function and the failure to remove digoxin through blood dialysis
delayed the removal of digoxin from the patient’s body. Although
dialysis can treat hyperkalemia, it can also worsen digoxin intoxi-
cation by lowering the potassium level. Therefore, if the digoxin
concentration in a patient’s blood does not reach a normal level, the
potassium concentration in the serum should be carefully moni-
tored, and supplements should be given when the potassium
concentration is low. As a result of this delay, we were able to
observe the development of digoxin-induced encephalopathy and
the regaining of consciousness caused by the elimination of
digoxin.
Supportive treatment for digoxin intoxication should be per-
formed depending on the clinical symptoms. First, digoxin
administration should be terminated immediately. Activated
carbon can be used to lower the serum digoxin level in cases of
acute intoxication.
Digoxin antibodies (digoxin immune Fab, Digibind) can be
administered when the aforementioned treatments do not relieve
the patient’s symptoms. According to the study by Kelly and Smith
[12], the dosage of digoxin-speciﬁc antibodies can be calculated
using the following formula:
Dosage of Fab fragments ðmgÞ ¼ ½50;000 ðDaÞ
 total amount of digoxin in
the body ðmgÞ=molecular
weight of digoxin ð781 DaÞ
Approximately 90% of patients show the effects of the antibodies 19
minutes after injection. Generally, a signiﬁcant relief of symptoms
will be observed within 30e60 minutes after injection. Gastroin-
testinal symptoms are eliminated ﬁrst, followed by irregular heart
rhythms. Digoxin toxicity is expected to be relieved 3e4 hours after
the injection [13]. The half-life of the digoxin-speciﬁc Fab fragments
is approximately 17.1 hours, and symptoms are unlikely to recur
once the patient has been treated with the antibody. However, as
the half-life of digoxin is much longer than that of the digoxin-
speciﬁc Fab fragments, patients with renal failure and those whohave taken high amounts of digoxin may still be at a risk of
recurrent digoxin overdose and should be closely monitored [14].4. Conclusion
Digoxin is a drug that requires extensive education on its use.
Patients with kidney disease should have periodic checkups to
monitor renal function, levels of associated electrolytes, and the
serum drug concentration. They should also have periodic evalua-
tions of both possible drug interactions that could affect digoxin
absorption and metabolism and the patient’s drug administration
status and compliance.References
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